Journals / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 1

Lipoprotein-associated phospholipase A2 and carotid intima-media thickness in primary Sjögren syndrome

Pages
40–48
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our study suggests that the patients of pSS have a potential risk of atherosclerotic cardiovascular disease, independent of traditional cardiovascular risk factors and disease severity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate serum lipoprotein-associated phospholipase A2 (Lp-PLA2) level and carotid intima-media thickness in primary Sjögren syndrome (pSS) as an indicator of atherosclerosis.
📊
Key Findings & Data:Patients and methods: Between July 2019 and July 2020, a total of 33 female pSS patients (mean age: 44.5±11.2 years; range, 23 to 60 years) and 37 female age- and sex-matched healthy individuals (mean age: 40.9±7.2 years; range, 25 to 54 years) were included.
💡
Conclusion & Impact:Conclusion: Our study suggests that the patients of pSS have a potential risk of atherosclerotic cardiovascular disease, independent of traditional cardiovascular risk factors and disease severity.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to evaluate serum lipoprotein-associated phospholipase A2 (Lp-PLA2) level and carotid intima-media thickness in primary Sjögren syndrome (pSS) as an indicator of atherosclerosis. Patients and methods: Between July 2019 and July 2020, a total of 33 female pSS patients (mean age: 44.5±11.2 years; range, 23 to 60 years) and 37 female age- and sex-matched healthy individuals (mean age: 40.9±7.2 years; range, 25 to 54 years) were included. Carotid intima-media thickness and serum Lp-PLA2 levels were measured in the patient and control groups. Results: The patients had a higher median serum Lp-PLA2 of 560 (range, 108 to 1,222) ng/mL vs. 328 (range, 0 to 1,280) ng/mL in the controls (p=0.024) and a similar mean intima-media thickness of carotid artery (0.64±0.14 mm vs. 0.62±0.15 mm, respectively; p=0.595). Serum Lp-PLA2 was positively correlated with platelet count (r=0.411, p=0.018) and negatively correlated with erythrocyte sedimentation rate (r=-0.409, p=0.018). The mean value of carotid intima-media thickness was positively correlated with disease duration (r=0.316, p=0.074) and was negatively correlated with the level of leucocyte (r=-0.458, p=0.007). Conclusion: Our study suggests that the patients of pSS have a potential risk of atherosclerotic cardiovascular disease, independent of traditional cardiovascular risk factors and disease severity.

🔖

Cite This Article

KAPLANOĞLU, H., GÜLTUNA, S., SANDIKÇI, S. C., AYDIN, F. N., ATEŞ, F. S. Ö. (2022). Lipoprotein-associated phospholipase A2 and carotid intima-media thickness in primary Sjögren syndrome. Archives of Rheumatology, Cilt: 37 - Sayı: 1, 40–48. https://ajindex.com/articles/447966

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47
  2. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008;121(10 Suppl 1):S3-8
  3. Yong WC, Sanguankeo A, Upala S. Association between primary Sjögren's syndrome, cardiovascular and cerebrovascular disease: A systematic review and meta-analysis. Clin Exp Rheumatol 2018;36 Suppl 112:190-7
  4. Beltai A, Barnetche T, Daien C, Lukas C, GaujouxViala C, Combe B, et al. Cardiovascular morbidity and mortality in primary Sjögren’s syndrome: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2020;72:131-9
  5. Pérez-De-Lis M, Akasbi M, Sisó A, Diez-Cascon P, Brito-Zerón P, Diaz-Lagares C, et al. Cardiovascular risk factors in primary Sjögren's syndrome: A casecontrol study in 624 patients. Lupus 2010;19:941-8
  6. Freire de Carvalho J, Sherer Y, Shoenfeld Y. The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost 2007;98:1157-9
  7. Khakpour H, Frishman WH. Lipoproteinassociated phospholipase A2: An independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Cardiol Rev 2009;17:222-9
  8. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag 2006;2:153-6
  9. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoproteinassociated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101:51F-57F
  10. Pezzano A, La Carrubba S, Gullace G. Carotid intimamedia thickness. J Cardiovasc Med (Hagerstown) 2006;7:555-9
  11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the AmericanEuropean Consensus Group. Ann Rheum Dis 2002;61:554-8
  12. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2016;75:382-9
  13. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warn